Side-by-side · Research reference

SurvodutidevsVilon

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 3HUMAN-REVIEWED25/54 cited

BAnimal-StrongHUMAN-REVIEWED13/49 cited

Survodutide

GLP-1/Glucagon Dual Agonist · Phase 3

Once weeklyFrequency

Phase 3Development stageRubino 2026

GLP-1/GCGRDual targetZimmermann 2026

SQ · Once Weekly

Vilon

Khavinson Bioregulator · Dipeptide

2 AADipeptide

T-helperStimulatesLinkova 2011

MouseModel basisKhavinson 2002

Literature lacks standardised clinical route

01Mechanism of Action

Parameter

Survodutide

Vilon

Primary target

GLP-1 receptor and glucagon receptor (GCGR)Yathindra 2026 Zimmermann 2026

Immune cell differentiation pathways, chromatin modification

Pathway

Central: CVOs → hypothalamic appetite regulation. Peripheral: GLP-1R → incretin effect; GCGR → hepatic lipid metabolism, energy expenditureZimmermann 2026 Long 2026

Vilon → Thymocyte sphingomyelinase activation → T-helper & cytotoxic T-cell differentiation; epigenetic suppression of aging markers (CCL11, HMGB1)

Downstream effect

Decreased energy intake, increased energy expenditure, improved glucose homeostasis, hepatic fat reductionZimmermann 2026 Yathindra 2026

Enhanced T-cell differentiation (CD4+, CD8+, B-cells), thymocyte proliferation, modulated IL-1β comitogenic activity, proposed chromatin decondensation in aged lymphocytesLinkova 2011 Khavinson 2002 Lezhava 2023

Feedback intact?

—

Unknown — no HPA/HPG axis data

Origin

—

Synthetic dipeptide derived from Khavinson thymic peptide extraction studies (Thymalin fraction)Morozov 1997

Antibody development

—

02Dosage Protocols

Parameter

Survodutide

Vilon

Standard dose

Not yet disclosed (Phase 3 ongoing)

SYNCHRONIZE Phase 3 program underway.Rubino 2026

No clinical standard — literature lacks human dosing

Russian practice: often combined with other Khavinson peptides; no FDA/EMA trials.

Frequency

Once weekly

Unknown — literature does not specify chronic administration protocols

Route

SubcutaneousYathindra 2026

Likely SQ or oral (Khavinson school uses both); no published ROA validation

Evidence basis

Phase 2 RCT (obesity) · Phase 3 ongoing

Mouse / in vitro only

Phase 2 findings

Significant weight loss and metabolic marker improvementYathindra 2026

—

MASH indication

Under investigation for MASH-cirrhosisPatil 2026 Andonie 2026

—

Animal model dose

—

In vitro: 0.01–10 μg/mL culture medium (mouse thymocytes)

Not translatable to human mg/kg without pharmacokinetic data.

Duration

—

Not characterised in humans

Half-life

—

Not published — dipeptides typically <10 min plasma t½

03Metabolic / Fat Loss Evidence

Parameter

Survodutide

Vilon

Primary fat target

Total body weight, visceral adipose tissue

—

Weight loss mechanism

Dual action: decreased energy intake + increased energy expenditureZimmermann 2026

—

Phase 2 efficacy

Significant weight loss demonstrated

Specific percentage not disclosed in abstracts.

—

Metabolic markers

Improvements in ALT, AST, LDL levels; significant ALT reduction (MD -22.10 vs placebo)Yathindra 2026 Abulehia 2026 Andonie 2026

—

MRI-PDFF reduction

Hepatic fat reduction demonstrated in MASH trialsAndonie 2026

—

Network meta-analysis

Favorable efficacy profile vs other glucagon receptor agonists

—

Hepatic requirement

Hepatic GCGR required for maximal weight loss and metabolic effectsLong 2026

—

Energy expenditure

Increased energy expenditure contributes to weight lossZimmermann 2026

—

Comparative efficacy

Network meta-analysis shows competitive efficacy in GRA class

—

04Side Effects & Safety

Parameter

Survodutide

Vilon

GI symptoms

Diarrhea, nausea, fatigue — class effect of GLP-1 agonists

—

Safety profile

Network meta-analysis: comparable safety to other GRAs

—

Serious adverse events

Monitored in Phase 2/3; no unique safety signals reported

Detailed SAE data pending Phase 3 completion.

—

Injection site reactions

Expected with subcutaneous administration

—

Glucagon-related effects

Potential for tachycardia, increased blood pressure — theoretical glucagon effect

—

Human safety data

—

Absent from PubMed-indexed literature

Theoretical risk

—

Immune hyperactivation in autoimmune-prone individuals (T-cell differentiation enhancement)

Antibody formation

—

Not reported; dipeptides generally low immunogenicity

Animal models

—

No adverse effects noted in mouse thymocyte or pineal lymphoid cultures

Absolute Contraindications

Survodutide

·Personal or family history of medullary thyroid carcinoma (class effect)
·Multiple endocrine neoplasia syndrome type 2

Vilon

·Active autoimmune disease (theoretical — no clinical data)

Relative Contraindications

Survodutide

·Severe GI disease (inflammatory bowel disease, gastroparesis)
·History of pancreatitis
·Cardiovascular disease (monitor closely for glucagon effects)

Vilon

·Pregnancy / lactation (no safety data)
·Acute infection with cytokine storm risk (immune modulation unknown)

05Administration Protocol

Parameter

Survodutide

Vilon

1. Reconstitution

Specific reconstitution protocol not yet publicly disclosed. Follow manufacturer instructions upon approval.

No clinical protocols exist in Western peer-reviewed literature. Russian gerontological practice may use 1–10 mg ranges, but dosing is empirical.

2. Injection site

Subcutaneous — abdomen, thigh, or upper arm. Rotate sites weekly to minimize injection site reactions.

Subcutaneous injection (common for Khavinson peptides) or oral (some bioregulators reportedly active orally due to small size). No validated ROA.

3. Timing

Once weekly, same day each week. Can be administered at any time of day, with or without meals.

Unknown — no circadian or meal-timing data. Khavinson school often recommends morning administration.

4. Storage

Store refrigerated (2–8 °C) until use. Do not freeze. Protect from light. Specific reconstituted storage duration pending labeling.

Likely lyophilised powder, refrigerated. Reconstitution protocols not published.

5. Needle

Subcutaneous injection with appropriate gauge needle (typically 27–31G). Use sterile technique.

—

06Stack Synergy

Survodutide

— no documented stacks

Vilon

+ Epitalon

Moderate

View Epitalon →

Both are Khavinson bioregulators targeting aging pathways. Epitalon (Ala-Glu-Asp-Gly) acts on telomerase and pineal function; Vilon on immune differentiation and chromatin decondensation. Combined in Russian gerontological protocols for multi-system aging intervention. Lezhava et al. (2023) tested both on aged lymphocyte chromatin, showing distinct epigenetic effects. Complementary, not synergistic in strict pharmacological sense.

Vilon: Empirical — no standard
Epitalon: Empirical — often 10 mg cycles
Frequency: Sequential or concurrent (literature ambiguous)
Primary benefit: Multi-system aging modulation (immune + pineal/circadian)

+ Thymalin

Weak

View Thymalin →

Thymalin is the parent polypeptide complex from which Vilon was isolated. Both target immune differentiation, but Thymalin is a complex mixture (multiple peptides), whereas Vilon is a purified dipeptide. Morozov & Khavinson (1997) described Vilon as a synthetic successor designed to replicate Thymalin's immunomodulatory effects with greater specificity. Redundant in practice; no published combination studies.

Vilon: No standard
Thymalin: 10–100 mg IM (polypeptide complex)
Primary benefit: Redundant — both target T-cell differentiation

Morozov 1997 Khavinson 2020